stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Debt to equity
Rhythm Pharmaceuticals, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 0.0× (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 37 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | −0.5× |
| PRAX Praxis Precision Medicines, Inc. compare | 0.0× |
| CORT Corcept Therapeutics Incorporated compare | 0.0× |
| ORKA Oruka Therapeutics, Inc. compare | 0.0× |
| RYTM Rhythm Pharmaceuticals, Inc. | 0.0× |
| ABVX Abivax SA Sponsored ADR compare | 0.0× |
| AXSM Axsome Therapeutics, Inc. compare | 1.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 1.9× |
| IONS Ionis Pharmaceuticals, Inc. compare | 3.1× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement